As the U.S. grapples with the lasting effects of the Covid-19 pandemic, it is important to highlight the ongoing challenges faced by the 7 million immunocompromised Americans. For them, the battle ...
Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have ...
The expanded authorization was based on data from the phase 2/3 BLAZE-1 trial. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab plus ...
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking ...
The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients ...
A new Alzheimer’s disease monoclonal antibody treatment that takes aim at a new target for the progressive disease has shown promising results, according to Boston researchers. The Mass General ...
Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient ...
The pause affects Sotrovimab from GlaxoSmithKline. The federal government is sharply pulling back on one of the monoclonal antibody treatments authorized for COVID-19, pausing its use across eight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback